Loading clinical trials...
Loading clinical trials...
This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled, crossover study to investigate ganaxolone treatment in children with fragile x syndrome (FXS). The objective of t...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Marinus Pharmaceuticals
Collaborators
NCT06560242 · Fragile X Syndrome
NCT06139172 · Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis, and more
NCT05418049 · Fragile X Syndrome
NCT07439510 · Fragile X Syndrome (FXS)
NCT06957054 · Fragile X Syndrome (FXS), Neurotypical Adults
M.I.N.D. Institute at University of California at Davis Medical Center
Sacramento, California
Antwerp University Hospital
Edegem
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions